隨著研究的發展，fluoroquinolone的選擇於結核治療指引有所不同。經過活性結構的修飾，新一代fluoroquinolone展現卓越的抗結核效果；本文藉由探討fluoroquinolone的結構相關特性與藥物動力學表現，並參照臨床使用fluoroquinolone於結核治療的試驗結果，逐一比較不同世代的 fluoroquinolone 如 ofloxacin、ciprofloxacinlevofloxacinmoxifloxacin、gatifloxacin及sparfloxacin在長期結核病治療的有效性與安全性。最後彙整治療指引，再次檢視fluoroquinolone於結核治療的角色、使用時機與相關應注意的事項，希望提供臨床選擇使
用fluoroquinolone之參考依據。

Fluoroquinolones are used to treat tuberculosis based on in vitro and clinical studies. Recently, WHO recommened later-generation of
fluoroquinolones, levofloxacin and moxifloxacin rather than ciprofloxacin as antituberculosis in the management of patients with ofloxacin resistance. Studies showing the different potency between older and newer-generation of fluoroquinolones in vitro and in vivo are discussed in this article. Besides,optimal policy was referred according to the pharmacodynamic properties of fluoroquinolones and the guidelines
of antituberculosis. We evaluated the
efficacy,susceptibility,pharmacodynamics and safety concern as clinical
factors to choose the most appropriate fluoroquinolone forantituberculosis.